N Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceuticals’ or ‘the Group’) is a listed biopharmaceutical company in China’s pharmaceutical industry operates more than 20 years. Group has an international outlook combined with China has established a solid drug development, clinical development, regulatory, manufacturing and sales and marketing business model, currently in the Chinese market a total of fourteen kinds of products.
Laboratorios SALVAT, S.A. (hereinafter “Salvat”) and Lee’s Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”, SEHK Stock Code: 0950), jointly announced today the signing of an exclusive License and Supply Agreement for the marketing and distribution of Duoxal® ear drops (patented combination solution of Ciprofloxacin and Fluocinolone Acetonide) in the People’s Republic of China, Hong Kong S.A.R., Macau S.A.R., and Taiwan and an option to add Thailand to the contractual territory.
Duoxal ear drops is a prescription medicine used to treat acute otitis media in patients with tympanostomy tubes (“AOMT”) and acute otitis externa (swimmer’s ear) in adults and children older than 6 months of age.
“We are pleased to enter into a partnership with Lee’s Pharm, a company that complements our development capabilities with a deep knowledge of Greater China,” said Alberto Bueno, Chief Executive Officer of Salvat. “This long-term collaboration is a major milestone for Salvat, as we continue to grow our presence in international markets and to expand the Duoxal® footprint across multiple territories.”
“We are extremely excited about entering into an exclusive partnership with Salvat to register and market Duoxal® in our territory,” said Dr. Li Xiaoyi, Chief Executive Officer and Executive Director of Lee’s Pharm. “We believe that, as a novel combination product, Duoxal® can address the medical needs of those patients suffering from ear infections. We’re looking forward to collaborating closely with Salvat to initiate the drug registration process.”
Related posts:
UM SOM Develop a Vaccine To Prevent a Group of Deadly Bacterial Infections
Researchers Suggest Make a Way For TB drugs More Efficacious To Aganist Other Disease
Results From STRIVE Trial Of Enzalutamide Versus Bicalutamide In CRPC Published In Journal Of Clinical Oncology
Asian American Adults HBV Screening Can help Prevent the Onset of Liver Disease